Anzeige
Mehr »
Login
Montag, 30.03.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 922351 ISIN: DK0010287234 Ticker-Symbol: LDB 
Tradegate
30.03.20
15:43 Uhr
25,780 Euro
-0,320
-1,23 %
Branche
Pharma
Aktienmarkt
OMX Copenhagen 25
1-Jahres-Chart
H LUNDBECK A/S Chart 1 Jahr
5-Tage-Chart
H LUNDBECK A/S 5-Tage-Chart
RealtimeGeldBriefZeit
25,760
26,120
18:45
25,790
25,970
18:45

Aktuelle News zur H LUNDBECK Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:35Lundbeck adds a Parkinson's flop to its list of setbacks, writing off a $1.1 billion deal on mid-stage failure-
12:31Lundbeck drops Parkinson's drug acquired in €905m deal1
FrLundbeck's Lu AG06466 flunks mid-stage study; shares down 4%-
H LUNDBECK Aktie jetzt für 4€ handeln
FrH LUNDBECK A/S: Lundbeck announces phase IIa study results of Lu AG06466 in adults with Tourette Syndrome-
FrLundbeck cuts guidance after failed Parkinson's study-
FrH LUNDBECK A/S: Lundbeck reports headline results from phase IIa AMBLED study of foliglurax in Parkinson's disease1
FrBRIEF-Lundbeck Reports Headline Results From Phase Iia Ambled Study Of Foliglurax In Parkinson's Disease-
DiH LUNDBECK A/S: Lundbeck held its Annual General Meeting on 24 March 2020 at the company's registered office-
DiXFRA DIVIDEND/INTEREST INFORMATION - 25.03.2020 - 1366FOLGENDE WERTPAPIERE WERDEN AM 24.03.2020 CUM DIVIDENDE/ZINSEN UND AM 25.03.2020 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL BE 24.03.2020. THE EX-DIVIDEND/INTEREST...
► Artikel lesen
04.03.BRIEF-Lundbeck Gets Grant From Michael J. Fox Foundation For Parkinson's Disease Research-
04.03.H LUNDBECK A/S: Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson's disease research-
02.03.H LUNDBECK A/S: Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties1
26.02.H LUNDBECK A/S: Notice of Annual General Meeting2
26.02.Lundbeck's Pullback Makes It Worth Considering Again2
24.02.Lundbeck gets US approval for migraine drug at heart of Alder takeover1
24.02.Lundbeck gets FDA nod for migraine prevention drug Vyepti-
24.02.Lundbeck's Alder Bio Bet Pays Off With FDA Approval of Migraine Drug1
22.02.The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B2
22.02.UPDATE 1-U.S. FDA approves Lundbeck's migraine prevention therapy6
22.02.BRIEF-U.S. FDA Approves Lundbeck's Vyepti2
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1